5fpf - Revision history

OCA at 13:17, 26 July 2023

OCA — Wed, 26 Jul 2023 13:17:23 GMT

←Older revision		Revision as of 13:17, 26 July 2023
Line 3:		Line 3:
	<StructureSection load='5fpf' size='340' side='right'caption='[[5fpf]], [[Resolution\|resolution]] 2.60Å' scene=''>		<StructureSection load='5fpf' size='340' side='right'caption='[[5fpf]], [[Resolution\|resolution]] 2.60Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[5fpf]] is a 4 chain structure with sequence from [~~http~~://en.wikipedia.org/wiki/~~Human Human~~]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5FPF OCA]. For a <b>guided tour on the structure components</b> use [~~http~~://proteopedia.org/fgij/fg.htm?mol=5FPF FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[5fpf]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5FPF OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5FPF FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=5ZI:4-[3-(4-OXO-3,4-DIHYDROQUINAZOLIN-2-+YL)PROPANAMIDO]-N-(QUINOLIN-8-YL)BENZAMIDE'>5ZI</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene>~~</td></tr>~~	+	</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 2.6Å</td></tr>
-	~~<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[5fpg\|5fpg]]~~</td></tr>	+	<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=5ZI:4-[3-(4-OXO-3,4-DIHYDROQUINAZOLIN-2-+YL)PROPANAMIDO]-N-(QUINOLIN-8-YL)BENZAMIDE'>5ZI</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://proteopedia.org/fgij/fg.htm?mol=5fpf FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5fpf OCA], [~~http~~://pdbe.org/5fpf PDBe], [~~http~~://www.rcsb.org/pdb/explore.do?structureId=5fpf RCSB], [~~http~~://www.ebi.ac.uk/pdbsum/5fpf PDBsum], [~~http~~://prosat.h-its.org/prosat/prosatexe?pdbcode=5fpf ProSAT]</span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5fpf FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5fpf OCA], [https://pdbe.org/5fpf PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5fpf RCSB], [https://www.ebi.ac.uk/pdbsum/5fpf PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5fpf ProSAT]</span></td></tr>
	</table>		</table>
	== Function ==		== Function ==
-	[~~[http~~://www.uniprot.org/uniprot/TNKS2_HUMAN TNKS2_HUMAN]] Poly-ADP-ribosyltransferase involved in various processes such as Wnt signaling pathway, telomere length and vesicle trafficking. Acts as an activator of the Wnt signaling pathway by mediating poly-ADP-ribosylation of AXIN1 and AXIN2, 2 key components of the beta-catenin destruction complex: poly-ADP-ribosylated target proteins are recognized by RNF146, which mediates their ubiquitination and subsequent degradation. Also mediates poly-ADP-ribosylation of BLZF1 and CASC3, followed by recruitment of RNF146 and subsequent ubiquitination. Mediates poly-ADP-ribosylation of TERF1, thereby contributing to the regulation of telomere length. May also regulate vesicle trafficking and modulate the subcellular distribution of SLC2A4/GLUT4-vesicles.<ref>PMID:11802774</ref> <ref>PMID:11739745</ref> <ref>PMID:19759537</ref> <ref>PMID:21478859</ref>	+	[https://www.uniprot.org/uniprot/TNKS2_HUMAN TNKS2_HUMAN] Poly-ADP-ribosyltransferase involved in various processes such as Wnt signaling pathway, telomere length and vesicle trafficking. Acts as an activator of the Wnt signaling pathway by mediating poly-ADP-ribosylation of AXIN1 and AXIN2, 2 key components of the beta-catenin destruction complex: poly-ADP-ribosylated target proteins are recognized by RNF146, which mediates their ubiquitination and subsequent degradation. Also mediates poly-ADP-ribosylation of BLZF1 and CASC3, followed by recruitment of RNF146 and subsequent ubiquitination. Mediates poly-ADP-ribosylation of TERF1, thereby contributing to the regulation of telomere length. May also regulate vesicle trafficking and modulate the subcellular distribution of SLC2A4/GLUT4-vesicles.<ref>PMID:11802774</ref> <ref>PMID:11739745</ref> <ref>PMID:19759537</ref> <ref>PMID:21478859</ref>

	==See Also==		==See Also==
Line 17:		Line 17:
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
-	[[Category: ~~Human~~]]	+	[[Category: Homo sapiens]]
	[[Category: Large Structures]]		[[Category: Large Structures]]
-	[[Category: Haikarainen, T]]	+	[[Category: Haikarainen T]]
-	[[Category: Lehtio, L]]	+	[[Category: Lehtio L]]
-	~~[[Category: Adp- ribosylation]]~~	+
-	~~[[Category: Diphtheria toxin like fold]]~~	+
-	~~[[Category: Protein-ligand complex]]~~	+
-	~~[[Category: Transferase]]~~	+
-	~~[[Category: Transferase-transferase inhibitor complex~~]]	+

OCA at 07:30, 6 May 2020

OCA — Wed, 06 May 2020 07:30:28 GMT

←Older revision		Revision as of 07:30, 6 May 2020
Line 1:		Line 1:

	==Crystal structure of human tankyrase 2 in complex with TA-91==		==Crystal structure of human tankyrase 2 in complex with TA-91==
-	<StructureSection load='5fpf' size='340' side='right' caption='[[5fpf]], [[Resolution\|resolution]] 2.60Å' scene=''>	+	<StructureSection load='5fpf' size='340' side='right'caption='[[5fpf]], [[Resolution\|resolution]] 2.60Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[5fpf]] is a 4 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5FPF OCA]. For a <b>guided tour on the structure components</b> use [http://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=5FPF FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[5fpf]] is a 4 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5FPF OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=5FPF FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=5ZI:4-[3-(4-OXO-3,4-DIHYDROQUINAZOLIN-2-+YL)PROPANAMIDO]-N-(QUINOLIN-8-YL)BENZAMIDE'>5ZI</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr>	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=5ZI:4-[3-(4-OXO-3,4-DIHYDROQUINAZOLIN-2-+YL)PROPANAMIDO]-N-(QUINOLIN-8-YL)BENZAMIDE'>5ZI</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr>
	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[5fpg\|5fpg]]</td></tr>		<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[5fpg\|5fpg]]</td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=5fpf FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5fpf OCA], [http://pdbe.org/5fpf PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5fpf RCSB], [http://www.ebi.ac.uk/pdbsum/5fpf PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5fpf ProSAT]</span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=5fpf FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5fpf OCA], [http://pdbe.org/5fpf PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5fpf RCSB], [http://www.ebi.ac.uk/pdbsum/5fpf PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5fpf ProSAT]</span></td></tr>
	</table>		</table>
	== Function ==		== Function ==
	[[http://www.uniprot.org/uniprot/TNKS2_HUMAN TNKS2_HUMAN]] Poly-ADP-ribosyltransferase involved in various processes such as Wnt signaling pathway, telomere length and vesicle trafficking. Acts as an activator of the Wnt signaling pathway by mediating poly-ADP-ribosylation of AXIN1 and AXIN2, 2 key components of the beta-catenin destruction complex: poly-ADP-ribosylated target proteins are recognized by RNF146, which mediates their ubiquitination and subsequent degradation. Also mediates poly-ADP-ribosylation of BLZF1 and CASC3, followed by recruitment of RNF146 and subsequent ubiquitination. Mediates poly-ADP-ribosylation of TERF1, thereby contributing to the regulation of telomere length. May also regulate vesicle trafficking and modulate the subcellular distribution of SLC2A4/GLUT4-vesicles.<ref>PMID:11802774</ref> <ref>PMID:11739745</ref> <ref>PMID:19759537</ref> <ref>PMID:21478859</ref>		[[http://www.uniprot.org/uniprot/TNKS2_HUMAN TNKS2_HUMAN]] Poly-ADP-ribosyltransferase involved in various processes such as Wnt signaling pathway, telomere length and vesicle trafficking. Acts as an activator of the Wnt signaling pathway by mediating poly-ADP-ribosylation of AXIN1 and AXIN2, 2 key components of the beta-catenin destruction complex: poly-ADP-ribosylated target proteins are recognized by RNF146, which mediates their ubiquitination and subsequent degradation. Also mediates poly-ADP-ribosylation of BLZF1 and CASC3, followed by recruitment of RNF146 and subsequent ubiquitination. Mediates poly-ADP-ribosylation of TERF1, thereby contributing to the regulation of telomere length. May also regulate vesicle trafficking and modulate the subcellular distribution of SLC2A4/GLUT4-vesicles.<ref>PMID:11802774</ref> <ref>PMID:11739745</ref> <ref>PMID:19759537</ref> <ref>PMID:21478859</ref>
		+
		+	==See Also==
		+	*[[Poly(ADP-ribose) polymerase 3D structures\|Poly(ADP-ribose) polymerase 3D structures]]
	== References ==		== References ==
	<references/>		<references/>
Line 15:		Line 18:
	</StructureSection>		</StructureSection>
	[[Category: Human]]		[[Category: Human]]
		+	[[Category: Large Structures]]
	[[Category: Haikarainen, T]]		[[Category: Haikarainen, T]]
	[[Category: Lehtio, L]]		[[Category: Lehtio, L]]

OCA at 12:42, 6 November 2017

OCA — Mon, 06 Nov 2017 12:42:55 GMT

←Older revision		Revision as of 12:42, 6 November 2017
Line 3:		Line 3:
	<StructureSection load='5fpf' size='340' side='right' caption='[[5fpf]], [[Resolution\|resolution]] 2.60Å' scene=''>		<StructureSection load='5fpf' size='340' side='right' caption='[[5fpf]], [[Resolution\|resolution]] 2.60Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[5fpf]] is a 4 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5FPF OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5FPF FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[5fpf]] is a 4 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5FPF OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5FPF FirstGlance]. <br>
	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=5ZI:4-[3-(4-OXO-3,4-DIHYDROQUINAZOLIN-2-+YL)PROPANAMIDO]-N-(QUINOLIN-8-YL)BENZAMIDE'>5ZI</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr>		</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=5ZI:4-[3-(4-OXO-3,4-DIHYDROQUINAZOLIN-2-+YL)PROPANAMIDO]-N-(QUINOLIN-8-YL)BENZAMIDE'>5ZI</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr>
	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[5fpg\|5fpg]]</td></tr>		<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[5fpg\|5fpg]]</td></tr>
Line 14:		Line 14:
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Human]]
	[[Category: Haikarainen, T]]		[[Category: Haikarainen, T]]
	[[Category: Lehtio, L]]		[[Category: Lehtio, L]]

OCA at 19:14, 15 December 2016

OCA — Thu, 15 Dec 2016 19:14:52 GMT

←Older revision		Revision as of 19:14, 15 December 2016
Line 1:		Line 1:
-	'''Unreleased structure'''

-	~~The entry~~ 5fpf is ~~ON HOLD until Paper Publication~~	+	==Crystal structure of human tankyrase 2 in complex with TA-91==
-		+	<StructureSection load='5fpf' size='340' side='right' caption='[[5fpf]], [[Resolution\|resolution]] 2.60Å' scene=''>
-	~~Authors~~: ~~Haikarainen~~, T., ~~Lehtio~~, L.	+	== Structural highlights ==
-		+	<table><tr><td colspan='2'>[[5fpf]] is a 4 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5FPF OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5FPF FirstGlance]. <br>
-	~~Description~~: ~~Crystal structure~~ of ~~human tankyrase~~ 2 in complex ~~with TA~~-91	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=5ZI:4-[3-(4-OXO-3,4-DIHYDROQUINAZOLIN-2-+YL)PROPANAMIDO]-N-(QUINOLIN-8-YL)BENZAMIDE'>5ZI</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr>
-	[[Category: ~~Unreleased Structures~~]]	+	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[5fpg\|5fpg]]</td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5fpf FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5fpf OCA], [http://pdbe.org/5fpf PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5fpf RCSB], [http://www.ebi.ac.uk/pdbsum/5fpf PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5fpf ProSAT]</span></td></tr>
		+	</table>
		+	== Function ==
		+	[[http://www.uniprot.org/uniprot/TNKS2_HUMAN TNKS2_HUMAN]] Poly-ADP-ribosyltransferase involved in various processes such as Wnt signaling pathway, telomere length and vesicle trafficking. Acts as an activator of the Wnt signaling pathway by mediating poly-ADP-ribosylation of AXIN1 and AXIN2, 2 key components of the beta-catenin destruction complex: poly-ADP-ribosylated target proteins are recognized by RNF146, which mediates their ubiquitination and subsequent degradation. Also mediates poly-ADP-ribosylation of BLZF1 and CASC3, followed by recruitment of RNF146 and subsequent ubiquitination. Mediates poly-ADP-ribosylation of TERF1, thereby contributing to the regulation of telomere length. May also regulate vesicle trafficking and modulate the subcellular distribution of SLC2A4/GLUT4-vesicles.<ref>PMID:11802774</ref> <ref>PMID:11739745</ref> <ref>PMID:19759537</ref> <ref>PMID:21478859</ref>
		+	== References ==
		+	<references/>
		+	__TOC__
		+	</StructureSection>
		+	[[Category: Haikarainen, T]]
	[[Category: Lehtio, L]]		[[Category: Lehtio, L]]
-	[[Category: ~~Haikarainen, T~~]]	+	[[Category: Adp- ribosylation]]
		+	[[Category: Diphtheria toxin like fold]]
		+	[[Category: Protein-ligand complex]]
		+	[[Category: Transferase]]
		+	[[Category: Transferase-transferase inhibitor complex]]

OCA at 12:59, 16 December 2015

OCA — Wed, 16 Dec 2015 12:59:47 GMT

←Older revision		Revision as of 12:59, 16 December 2015
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

-	The entry 5fpf is ON HOLD	+	The entry 5fpf is ON HOLD until Paper Publication

	Authors: Haikarainen, T., Lehtio, L.		Authors: Haikarainen, T., Lehtio, L.

OCA: Protected "5fpf" [edit=sysop:move=sysop]

OCA — Wed, 09 Dec 2015 12:52:07 GMT

Protected "5fpf" [edit=sysop:move=sysop]

←Older revision

Revision as of 12:52, 9 December 2015

OCA: New page: '''Unreleased structure''' The entry 5fpf is ON HOLD Authors: Haikarainen, T., Lehtio, L. Description: Crystal structure of human tankyrase 2 in complex with TA-91 [[Category: Unreleas...

OCA — Wed, 09 Dec 2015 12:52:05 GMT

New page: '''Unreleased structure''' The entry 5fpf is ON HOLD Authors: Haikarainen, T., Lehtio, L. Description: Crystal structure of human tankyrase 2 in complex with TA-91 [[Category: Unreleas...

New page

'''Unreleased structure'''

The entry 5fpf is ON HOLD

Authors: Haikarainen, T., Lehtio, L.

Description: Crystal structure of human tankyrase 2 in complex with TA-91
[[Category: Unreleased Structures]]
[[Category: Lehtio, L]]
[[Category: Haikarainen, T]]